MONTREAL, March 7, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) welcomes the Government of Alberta's decision to publicly reimburse Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan injection) for eligible patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). With this announcement, Alberta joins Ontario and Nova Scotia in providing public access to this radioligand therapy, expanding treatment options for patients across Canada.
Read more at newswire.caThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Tesla%20Inc%20tesla%20by-%20Iv-olga%20via%20Shutterstock(1).jpg)
/Stickers%20with%20AMD%20Radeon%20and%20Nvidia%20GeForce%20RTX%20graphics%20on%20new%20laptop%20computer%20by%20Piotr%20Swat%20via%20Shutterstock.jpg)
/Nvidia%20logo%20by%20Konstantin%20Savusia%20via%20Shutterstock.jpg)